Immunic, inc. reports first quarter 2023 financial results and provides corporate update

– positive results from phase 1b clinical trial of imu-856 in celiac disease provide proof-of-concept for  a new therapeutic approach  to treat gastrointestinal diseases by promoting regeneration of bowel architecture – – interim results from phase 2 calliper trial of vidofludimus calcium in progressive multiple sclerosis expected in the second half of 2023 – – $97.1 million in cash, cash equivalents and investments expected to fund immunic into the fourth quarter of 2024 – – webcast to be held today, may 11, 2023, at 8:00 am et – new york , may 11, 2023 /prnewswire/ --  immunic, inc.  (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced financial results for the first quarter ended march 31, 2023, and provided a corporate update. "in the first quarter of 2023, we reported outstanding results from two key clinical programs.
IMUX Ratings Summary
IMUX Quant Ranking